Featured Editorial

1. 4 Delivery Science Lessons For RNA Developers 11/11/2026

   Drawing on published science, current guidance, and the author's own perspective, four delivery science lessons become clear for RNA developers.

2. Rethinking GLP-1 Delivery Beyond The Needle 11/6/2026

   To succeed with GLP-1s in 2027, drug developers must look beyond the active ingredient. Route of administration, absorption, and patient use are key factors.

3. Metabolic Interventions Improve Cancer Treatment Delivery 11/4/2026

   Could effective drug delivery depend not only on getting more therapy into a tumor but also on changing the tumor’s biological response to treatment?

4. FDA Rethinks Skin Sensitization Testing For Generic Transdermal And Topical Delivery Systems 11/3/2026

   The FDA has released a new draft guidance, Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs. The document is set to replace the 2023 version.

5. Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions 10/30/2026

   This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.

6. Built To Avoid Risk: How Industry Norms Stall Drug Discovery 10/28/2026

   At Discovery & Development US 2026 in San Diego, discovery leaders named the industry norms they would change.

7. Does Drug Discovery Anticipate Delivery? 10/28/2026

   In this article, Chief Editor Tom von Gunden considers the relationship between drug discovery and drug delivery. His commentary includes reflections on conversations and encounters from the Discovery & Development US conference, where formulation and delivery topics were also in the air and on the agenda. 

8. Antibody–Oligonucleotide Conjugates, Part 3: Analytical Control 10/23/2026

   Let's delve into analytical control strategy, OAR/DAR measurement, bioanalytical characterization, stability and formulation, and more.

9. Designing For Precision: How Delivery Is Shaping Cancer Treatment 10/19/2026

   Precision oncology has transformed who receives treatment and what biology we target. The next frontier is designing where therapeutic activity occurs.

10. Antibody–Oligonucleotide Conjugates, Part 2: Manufacturing 10/16/2026

    Let's delve into manufacturing strategy, conjugation chemistry, process development and scale-up, and purification: the central manufacturing challenge.